Tag - Research Capital

Markets

Research Capital ups Valeo Pharma PT on new drug licensing

Research Capital raised its price target for Valeo Pharma (CSE:VPH) to $1 (Canadian) from 70 cents and maintained a “speculative buy” rating after the company closed a $40-million (U.S.) non-dilutive financing from...

August 2, 2022

Markets

Research Capital downgrades Bellus Health on valuation, financing

Research Capital downgraded Bellus Health (NASDAQ:BLU) to “hold” from “speculative buy” and removed its previous $14.50 price target so “we can properly account for the new dilution” from a $153-million offering of new...

July 14, 2022

Markets

Research Capital starts Auxly Cannabis at buy; PT 50 cents (Canadian)

Research Capital initiated coverage of Auxly Cannabis Group (TSX:XLY) with a “buy” rating and price target of 50 cents (Canadian). The stock closed at 23 cents on Sept. 29. Auxly’s strategy to focus on building the...

September 30, 2021

Markets

Research Capital starts Aleafia Health at buy; PT 75 cents (Canadian)

Research Capital initiated coverage of Aleafia Health (TSX:AH) with a “buy” rating and price target of 75 cents (Canadian). The stock closed at 36 cents on Sept. 21. “We believe that Aleafia’s revenue growth will be...

September 22, 2021

Markets

Research Capital starts Perimeter Medical Imaging at speculative buy; PT $4.90 (Canadian)

Research Capital initiated coverage of Perimeter Medical Imaging (TSXV:PINK) with a “speculative buy” rating and a 12-month price target of $4.90 (Canadian). The stock closed at $3.37 on June 28. Perimeter is a medical...

June 29, 2021

Tag - Research Capital

Research Capital ups Valeo Pharma PT on new drug licensing

Research Capital downgrades Bellus Health on valuation, financing

Research Capital starts Auxly Cannabis at buy; PT 50 cents (Canadian)

Research Capital starts Aleafia Health at buy; PT 75 cents (Canadian)

Research Capital starts Perimeter Medical Imaging at speculative buy; PT $4.90 (Canadian)

General

More